On November 3, COVID-19 (2019-NCOV) antigen detection kit (Colloidal Gold method) and COVID-19 (2019-NCOV) antigen detection kit (Latex method) were approved by China National Medical Products Administration.

The prevention and control of the epidemic now requires a rapid detection method suitable for the grassroots.

Recently, a number of IVD companies reached cooperation.

Chairman of CAIVD, Mr. Song Haibo invited by Weimi Bio on Oct. 22nd to guide the work.

On October 26, Chemclin Diagnostics Corporation delivered the good news that it will be listed on the Sci-Tech innovation board in the IPO meeting.

In the clinical application of POCT more and more widely today, how to strengthen the quality management, avoid the management "blind area" and other issues, after hot discussion and practical exploration, has shown positive results and experience.

On October 20, 2020, Jiangsu Bioperfectus technologies Co., Ltd. and IntelliBio had reached a strategic cooperation. The two sides will work together to build intelligent solutions.

Recently, the centers for disease control and prevention in Africa and the African union commission jointly launched a Pathogen genome project (Pathogen Genomics Initiative, PGI).

On Oct. 20th, the Hurun Research Institute released the Hurun China Rich List 2020 a ranking of the richest individuals in China, with a wealth cut-off of CNY 2 billion, equivalent to US$290 million. Wealth calculations are from 28 August.

Reported by CCTV news on Oct. 16th, variety of countries need to enlarge the test method to speed up the diagnosis on COVID-19.

Mindray is expected to achieve the operating income of 14.855 billion yuan to 16.093 billion yuan in the first three quarters of 2020, a year-on-year growth of 20% to 30%.

On Sep. 25th, Upper Biotech applied for IPO was accepted by Shanghai Stock Exchange. At present, it has 7 listed enterprise on STAR Market, 2 registered upcoming companies and 5 waitings.

Shenzhen New Industries Biomedical Engineering Co., LTD., which was officially listed on the Gem of Shenzhen Stock Exchange on May 12, 2020,realized 97,0101,600 yuan of revenue, an increase of 31.06% over the same period last year.

From August to September 2020, the COVID-19 testing products of 5 companies around the world are included in the World Health Organization (WHO) Emergency Use Listing, of which 4 are Chinese in vitro diagnostics.

A joint research team have together developed a SENSR (SENsitive Splint-based one-pot isothermal RNA detection) technology that allows anyone to easily and quickly diagnose COVID-19 based on the RNA sequence of the virus.